Sibling Piggyback

CLINICAL TRIALS

 

DELIVERING HOPE TO PATIENTS

STAY INFORMED

Due to a high volume of inquiries, we are asking patients to follow us on twitter for new trial & enrollment announcements. The moment we know, we will let you know!

Hope Biosciences' HB-AdMSCs are adipose-derived mesenchymal stem cells that have been processed through our proprietary cell culture platform. Learn more about our product here.

 

For more information, follow the links below to the study listings on clinicaltrials.gov. Please visit our FAQ page for the answers to the most commonly asked questions. Have more questions? Please contact us!

 

Rheumatoid Arthritis

ClinicalTrials.gov Identifier: NCT03691909 Status: Enrollment Complete. Data analysis in progress. Official Title: A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis



Parkinson's Disease

ClinicalTrials.gov Identifier: NCT04064983 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease ClinicalTrials.gov Identifier: NCT04772378 Status: Enrollment Complete. Treatment in progress Official Title: HB-adMSCs for the Treatment of Parkinson's Disease



Spinal Cord Injury

ClinicalTrials.gov Identifier: NCT04064957 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury ClinicalTrials.gov Identifier: NCT03925649 Status: Enrollment Complete. Treatment complete. Follow up in progress. Collaborator: The University of Texas Health Science Center, Houston Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI



Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

ClinicalTrials.gov Identifier: NCT04063215 Status: Enrolling Contact: Contact: Steven Kosmach, MSN 713-500-7329 Steven.Kosmach@uth.tmc.edu Contact: Joiya Arrington, MSN (713) 500-7395 Joiya.Arrington@uth.tmc.edu Collaborator: The University of Texas Health Science Center, Houston Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy



Cerebral Palsy (Pediatric)

ClinicalTrials.gov Identifier: NCT04029896 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy.



Alzheimer's Disease

ClinicalTrials.gov Identifier: NCT04228666 Status: ON HOLD UNTIL FURTHER NOTICE Due to the recent events of COVID-19, we have decided to delay this protocol until it is safe to resume. Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease.



COVID-19 (Allogeneic Pre-treatment)

ClinicalTrials.gov Identifier: NCT04348435 Status: Enrollment Complete. Follow-up in progress. Official Title: A Phase 2, Randomized, Placebo-Controlled, Clinical Trial to Assess Efficacy of Allogeneic HB-adMSCs to Provide Immune Support Against Coronavirus Disease. This trial is open to:

  • Men, and women 18 years of age or older
  • Participant works in a capacity that is characterized as high-risk or very high-risk
  • High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19.
    • First responders, health care delivery and support staff (e.g., law enforcement, fire fighters, paramedics, doctors, nurses, and other hospital staff who must enter patients' rooms) exposed to individuals potentially having COVID-19.
    • Mortuary workers involved in preparing (e.g., for burial or cremation) the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death
  • Very High-Risk Exposure jobs are those with high potential for exposure to known or suspected sources of COVID-19 during specific medical, postmortem or laboratory procedures.
    • Health care workers (e.g., doctors, nurses, dentists, paramedics, emergency medical technicians) performing aerosol-generating procedures (e.g., intubation, cough induction procedures, bronchoscopies, some dental procedures and exams or invasive specimen collection) on known or suspected COVID-19 patients
    • Health care or laboratory personnel collecting or handling specimens from known or suspected COVID-19 patients (e.g., manipulating cultures from known or suspected COVID-19 patients)
    • Morgue workers performing autopsies, which generally involve aerosol-generating procedures, on the bodies of people who are known to have, or suspected of having, COVID-19 at the time of their death



COVID-19 (Autologous Pre-treatment)

Clinicaltrials.gov Identifier : NCT04349631 Enrollment: Complete Status: Treatments complete. Data analysis in progress. Visit hopebio.org for updated progress. Official Title: A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19



COVID-19 (Allogeneic Treatment)

Clinicaltrials.gov Identifier : TBD Enrollment: On Hold. Site: River Oaks Hopsital & United Memorial Medical Center Official Title: A Phase II, Randomized, Placebo-Controlled, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19



Osteoarthritis

ClinicalTrials.gov Identifier: Coming Soon Status: Enrollment Complete. Treatment complete, follow-up in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Hip Osteoarthritis



Amyotrophic Lateral Sclerosis (ALS)

ClinicalTrials.gov Identifier: NCT04514952 Status: Enrollment Complete. Treatment in progress. Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis



COVID-19 "Long Haulers"

ClinicalTrials.gov Identifier: Coming Soon Status: Enrollment Opening Soon Official Title: Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome Interested participants, please call the Hope Biosciences Stem Cell Research Foundation at 346-900-0340



Chronic Musculoskeletal Pain

ClinicalTrials.gov Identifier: NCT04711811 Status: Enrollment Complete, Treatment in Progress Official Title: Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Musculoskeletal Pain (CMP)



Primary Lateral Sclerosis (PLS)

ClinicalTrials.gov Identifier: Coming Soon Enrollment: Complete, Treatment in Progress More information coming soon.